2 Small-Cap Stocks With Big-Cap Potential
Cinderella stories aren't common in investing, but they do happen.
Perhaps the best recent example is Axsome Therapeutics (NASDAQ: AXSM). The company's market cap dipped to just $60 million in the final days of 2018, but promising results from a drug candidate aimed at treating depressive disorders propelled the stock onto Wall Street's radar weeks later. After a string of positive regulatory developments and promising late-stage clinical results over the course of last year, the pharma company ended 2019 with a market cap of $3.8 billion.
Investors will find it difficult to replicate those returns, but there are still a handful of small-cap stocks with big-cap potential. Two biopharma stocks that come to mind are TG Therapeutics (NASDAQ: TGTX) and Forty Seven (NASDAQ: FTSV). Both are developing promising treatments for blood cancers. Here's why investors may want to keep an eye on the duo in 2020.
Source Fool.com
